U.S. markets close in 5 hours 49 minutes
  • S&P 500

    3,690.02
    -3.21 (-0.09%)
     
  • Dow 30

    29,421.07
    -169.34 (-0.57%)
     
  • Nasdaq

    10,953.91
    +85.99 (+0.79%)
     
  • Russell 2000

    1,687.36
    +7.77 (+0.46%)
     
  • Crude Oil

    79.59
    +0.85 (+1.08%)
     
  • Gold

    1,652.80
    -2.80 (-0.17%)
     
  • Silver

    18.97
    +0.06 (+0.32%)
     
  • EUR/USD

    0.9654
    -0.0034 (-0.35%)
     
  • 10-Yr Bond

    3.7650
    +0.0680 (+1.84%)
     
  • GBP/USD

    1.0791
    -0.0066 (-0.61%)
     
  • USD/JPY

    144.2720
    +0.9520 (+0.66%)
     
  • BTC-USD

    19,189.31
    +255.73 (+1.35%)
     
  • CMC Crypto 200

    440.21
    +7.11 (+1.64%)
     
  • FTSE 100

    7,008.76
    -9.84 (-0.14%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

What Kind Of Shareholders Own Athira Pharma, Inc. (NASDAQ:ATHA)?

·4 min read

A look at the shareholders of Athira Pharma, Inc. (NASDAQ:ATHA) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership.

Athira Pharma is not a large company by global standards. It has a market capitalization of US$506m, which means it wouldn't have the attention of many institutional investors. In the chart below, we can see that institutional investors have bought into the company. Let's delve deeper into each type of owner, to discover more about Athira Pharma.

Check out our latest analysis for Athira Pharma

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Athira Pharma?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that Athira Pharma does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Athira Pharma's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Our data indicates that hedge funds own 5.1% of Athira Pharma. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Looking at our data, we can see that the largest shareholder is Perceptive Advisors LLC with 9.2% of shares outstanding. For context, the second largest shareholder holds about 5.6% of the shares outstanding, followed by an ownership of 5.4% by the third-largest shareholder.

A closer look at our ownership figures suggests that the top 12 shareholders have a combined ownership of 52% implying that no single shareholder has a majority.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Athira Pharma

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares in Athira Pharma, Inc.. In their own names, insiders own US$25m worth of stock in the US$506m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

General Public Ownership

With a 28% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Athira Pharma. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With an ownership of 9.2%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 5 warning signs for Athira Pharma you should be aware of, and 2 of them are concerning.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.